Similarly, tirzepatide, a dual GLP-1/GIP receptor agonist, achieved an average weight loss of 15% at 72 weeks in non-diabetic obese patients, with greater reductions observed at the higher 15 mg dose
Preclinical studies have demonstrated that GLP-1 RAs attenuate alcohol intake and reduce the ethanol-induced activation of mesolimbic dopaminergic pathways, highlighting their ability to modulate dysregulated reward circuitry associated with AUD [6,21]
IV League Hydration provides concierge mobile IV therapy for groups, events, private homes, offices, and hotels across Boston and Greater Boston
Background Hims 2025 revenue guidance has raised concerns that its become over-reliant on compounded semaglutide Critics question the sustainability of this business model now that the FDA has ended the semaglutide shortage On February 24, Hims & Hers management released aggressive full year guidance for 2025 that assumed $2.3-2.4 billion in revenue, an increase of nearly 60 percent compared to the prior year
